Insilico opens representative office in Singapore to expand business in Asia

15 April 2019

Insilico Biotechnology AG announces the opening of a representation in Singapore to develop its business in the Asia-Pacific (APAC) region and to strengthen support for its growing customer base. read more

Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production

21 February 2019

Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics. read more

Insilico talk: Predictive Biomanufacturing at the ELIXIR Innovation and SME Forum

11 October 2018

Insilico CEO Klaus Mauch will present a talk on Predicitve Biomanufacturing for the Factory of the Future as part of the ELIXIR Innovation and SME Forum "Data Driven Innovation in Industrial Biotechnology", organized by DECHEMA on 15-16 October 2018 | Frankfurt, Germany read more

Insilico is partner in a new joint research project to investigate neurodegenerative aspects of Alzheimer's disease

17 November 2017

The interdisciplinary consortium HiPSTAR tries to decipher the molecular mechanisms leading to Morbus Alzheimer. In particular, pathological alterations at the blood-brain-barrier are in the focus of this applied research project. The long-term goal of this collaborative effort is the development of new drugs and therapies targeting this predominant form of dementia. The project is coordinated by the University of Würzburg (Medical Faculty, Department of Tissue Engineering and Regenerative Medicine, TERM), and the Fraunhofer Institute for Molecular Biology and Applied Ecology, ScreeningPort, is a partner in the consortium. The German Ministry for Education and Research (Bundesministerium für Bildung und Forschung, BMBF) funds this project with an overall budget of 1.7 million Euro. read more